Condition (MeSH)
Unverricht-Lundborg Syndrome
ClinicalTrials.gov lists 5 trials for Unverricht-Lundborg Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Unverricht-Lundborg Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Unverricht-Lundborg Syndrome trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2015 | 1 |
| 2007 | 1 |
| 2006 | 2 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 5 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Unverricht-Lundborg Syndrome trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 3 |
| Observational | 1 |
How many Unverricht-Lundborg Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 2 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Unverricht-Lundborg Syndrome trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| UCB Pharma | 1 |
| UCB Pharma SA | 1 |
Which serious adverse events do Unverricht-Lundborg Syndrome trials report? (8)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 2 | 1 |
| Convulsion | 2 | 1 |
| Attention-seeking behavior | 1 | 1 |
| Clavicle fracture | 1 | 1 |
| Grand mal convulsion | 1 | 1 |
Showing 5 of 8 adverse events.
Which publications cover Unverricht-Lundborg Syndrome? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. | Epilepsy research | 2021 | Yes |
| Wearable monitoring of positive and negative myoclonus in progressive myoclonic epilepsy type 1. | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology | 2021 | Yes |
| Cystatin B is essential for proliferation and interneuron migration in individuals with EPM1 epilepsy. | EMBO molecular medicine | 2020 | Yes |
| Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies. | Epilepsia | 2016 | Yes |
| Unverricht-Lundborg disease. | Epileptic disorders : international epilepsy journal with videotape | 2016 | Yes |
Showing 5 of 8 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Progressive myoclonic epilepsy type 1 | Prevalence at birth | 1-9 / 100 000 | Finland | Not stated | Exact |
| Progressive myoclonic epilepsy type 1 | Prevalence at birth | 1-9 / 100 000 | Finland | Not stated | Exact |
| Progressive myoclonic epilepsy type 1 | Point prevalence | 1-9 / 100 000 | Finland | Not stated | Exact |
| Progressive myoclonic epilepsy type 1 | Point prevalence | 1-9 / 100 000 | Finland | Not stated | Unspecified |
| Progressive myoclonic epilepsy type 1 | Prevalence at birth | 1-9 / 100 000 | Finland | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Progressive myoclonic epilepsy type 1 | 308 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Progressive myoclonic epilepsy type 1 | 308 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.